Celcuity Inc

CELC

Company Profile

  • Business description

    Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company’s lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

  • Contact

    16305 36th Avenue North
    Suite 100
    MinneapolisMN55446
    USA

    T: +1 763 392-0767

    E: [email protected]

    https://www.celcuity.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    87

Stocks News & Analysis

stocks

Why I dislike dividend stocks

If you need income then buying dividend stocks makes perfect sense. But if you don’t then it makes little sense because it’s likely to limit building real wealth. Here’s what you should do instead.
stocks

Chart of the Week: Ramsay Health Care margins to rebound

Charts from our latest stock pitch for Ramsay Health Care show a clear path to improved profitability.
stocks

BlackRock earnings: Market gains and inflows drive AUM and revenue to record highs

We plan to raise our fair value estimate of BlackRock stock.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,375.9019.700.21%
CAC 408,108.3231.320.39%
DAX 4024,194.6913.320.06%
Dow JONES (US)46,253.3117.15-0.04%
FTSE 1009,428.463.710.04%
HKSE25,888.5122.09-0.09%
NASDAQ22,670.08148.380.66%
Nikkei 22548,277.74605.071.27%
NZX 50 Index13,389.1081.700.61%
S&P 5006,671.0626.750.40%
S&P/ASX 2009,068.4018.200.20%
SSE Composite Index3,916.234.020.10%

Market Movers